Biofrontera AG
DelistedCIK 1712641fmd_1ARPKC63EV6XMT8SF1XDHCZBGJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2020, 9 periods
Latest annual · FY2020
Millions- Total revenues
- 30
- Gross profit
- 27
- Operating income
- (8)
- Net income
- (11)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2017 to FY2020
- +36.1%
- Revenue, 5 yearsFY2015 to FY2020
- +49.0%
- Net income, 5 yearsFY2015 to FY2020
- n/m
Biofrontera AG financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2020 | FY2019 | Change | Source |
|---|---|---|---|---|
| Revenue | €30.3 million | €31.3 million | -2.9% | 20-F 2021-04-12 · proof |
| Gross profit | €26.8 million | €26.4 million | +1.6% | 20-F 2021-04-12 · proof |
| Operating income | -€7.6 million | -€23.4 million | 20-F 2021-04-12 · proof | |
| Net income | -€10.9 million | -€7.6 million | 20-F 2021-04-12 · proof | |
| Cash from operating activities | -€2.8 million | -€32.9 million | 20-F 2021-04-12 · proof | |
| Total assets | €56.4 million | €58.4 million | -3.4% | 20-F 2021-04-12 · proof |
| Total liabilities | €49 million | €48.4 million | +1.3% | 20-F 2021-04-12 · proof |
| Cash and cash equivalents | €16.5 million | €11.1 million | +48.8% | 20-F 2021-04-12 · proof |
- What was Biofrontera AG's revenue in fiscal 2020?
- Biofrontera AG reported revenue of €30.3 million for fiscal 2020 (the year ended Dec 31, 2020), against €31.3 million the year before (-2.9%). Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What was Biofrontera AG's gross profit in fiscal 2020?
- Biofrontera AG reported gross profit of €26.8 million for fiscal 2020 (the year ended Dec 31, 2020), against €26.4 million the year before (+1.6%). Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What was Biofrontera AG's operating income in fiscal 2020?
- Biofrontera AG reported operating income of -€7.6 million for fiscal 2020 (the year ended Dec 31, 2020), against -€23.4 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What was Biofrontera AG's net income in fiscal 2020?
- Biofrontera AG reported net income of -€10.9 million for fiscal 2020 (the year ended Dec 31, 2020), against -€7.6 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What was Biofrontera AG's cash from operating activities in fiscal 2020?
- Biofrontera AG reported cash from operating activities of -€2.8 million for fiscal 2020 (the year ended Dec 31, 2020), against -€32.9 million the year before. Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What are Biofrontera AG's total assets?
- As of Dec 31, 2020, Biofrontera AG reported total assets of €56.4 million, against €58.4 million a year earlier (-3.4%). Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What are Biofrontera AG's total liabilities?
- As of Dec 31, 2020, Biofrontera AG reported total liabilities of €49 million, against €48.4 million a year earlier (+1.3%). Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
- What are Biofrontera AG's cash and cash equivalents?
- As of Dec 31, 2020, Biofrontera AG reported cash and cash equivalents of €16.5 million, against €11.1 million a year earlier (+48.8%). Source: the 20-F filed with the SEC on Apr 12, 2021. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1712641&period_type=annual&limit=5"Information only, not investment advice.